Therapy of depression in dementia

Expert Review of Neurotherapeutics

Volumn 3, Issue 5, 2003, Pages 631-639

  Lavretsky, Helen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alternative; Antidepressants; Brain stimulation; Dementia; ECT; Elderly; Late life depression; Psychosocial; Selective serotonin reuptake inhibitors; Treatment

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOMIPRAMINE; CYCLOSPORIN A; DEXAMPHETAMINE; DIPHENHYDRAMINE; DONEPEZIL; FLUOXETINE; GALANTAMINE; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; KAVA; METHYLPHENIDATE; MIRTAZAPINE; NORTRIPTYLINE; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PAROXETINE; PEMOLINE MAGNESIUM; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; STATINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALERIAN;

AGED; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; PSYCHOSOCIAL CARE; REVIEW; SIDE EFFECT; VAGUS NERVE STIMULATION;

EID: 0042878237     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.5.631     Document Type: Review

References (82)

1. Blazer D, Williams CD. Epidemiology of dysphoria and depression in the elderly population. Am. J. Psychiatry 137, 927-932 (1980).
2. Caine ED, Lyness JM, King DA, Connors L. Clinical and etiological heterogeneity of mood disorders in elderly patients. In: Diagnosis and treatment of Depression in Late Life: Results of the NIH Consensus Development Conference. First Edition. Schneider LS, Reynolds CF, Lebowitz BD (Eds). American Psychiatric Press, Washinton DC, USA, 21-54 (1994).
3. Nelson JC. Diagnosing and treating depression in the elderly. J. Clin. Psychiatry 62(Suppl. 24), 18-22 (2001).
4. Ritchie K, Lovestone S. The dementias. Lancet 360, 1759-1766 (2002).
5. Lavretsky H, Kumar A. Clinically significant nonmajor depression: old concepts, new insights. Am. J. Geriatr. Psychiatry 10(3), 239-255 (2002).
6. Robinson RG, Bolduc PL, Price TR. Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at one and two years. Stroke 18, 579-584 (1987).
7. Simpson S, Allen H, Tomenson B et al. Neurological correlates of depressive symptoms in Alzheimer's disease and vascular dementia. J. Affect. Disord. 53, 129-136 (1999).
8. Kumar A, Cummings JL Depression in neurodegenerative disorders and related conditions in Alzheimer's disease and related conditions. In: Alzheimer's disease and Related disorders, Annual 2001. Gothier S, Cummings JL (Eds). Martin Dunitz, London, UK, 123-141 (2001).
9. Kitwood T. Toward a theory of dementia care: ethics and interaction. J. Clin. Ethics 9(1), 23-34 (1998).
10. Gareri P, De Fazio P, De Sarro G. Neuropharmacology of depression in aging and age-related diseases. Ageing Res. Rev. 1(1), 113-134 (2002).
11. Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol. Psychiatry 52(3), 243-252 (2002). Comprehensive overview of the current state of research on the topic.
12. Reifler BV. Arguments for abandoning the term pseudodementia. J. Am. Geriatr. Soc. 30, 665-668 (1982).
13. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer's disease: rationale and background. Am. J. Geriatr. Psychiatry 10(2), 129-141 (2002). The position statement of National Institute of Mental Health and American Association of Geriatric Psychiatry on depression in Alzheimer's disease.
14. Olin JT, Schneider LS, Katz IR et al. Provisional diagnostic criteria for depression of Alzheimer's disease. Am. J. Geriatr. Psychiatry 10, 125-128 (2002). The provisional consensus-based diagnostic criteria.
15. Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol. Aging 21, 845-861 (2000).
16. Vida S, Des Rosiers P, Carrier L, Gauthier S. Prevalence of depression in Alzheimer's disease and validity of research diagnostic criteria. J. Geriatr. Psychiatry Neurol. 7, 238-244 (1994).
17. Lyketsos CG, Steele C, Baker L et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J. Neuropsychiatry Clin. Neurosci. 9, 556-561 (1997).
18. Schweitzer I, Tuckwell V, O'Brien J, Ames D. Is late onset depression a prodrome to dementia? Int. J. Geriatr. Psychiatry 17, 997-1005 (2002).
19. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology 59(11), 1721-1729 (2002).
20. Weiner MF, Svedik D, Risser RC. What depressive symptoms are reported in Alzheimer's patients? Int. J. Geriatr. Psychiatry 12, 648-652 (1997).
21. Ballard C, Bannister C, Solis M, Oyebode F, Wilcock G. The prevalence, associations and symptoms of depression amongst dementia sufferers. J. Affect. Disord. 36(3-4), 135-144 (1996).
22. Pearlson GD, Ross CA, Lohr WD et al. Association between family history of affective disorder and the depressive syndrome of Alzheimer's disease. Am. J. Psychiatry 147, 452-456 (1990).
23. Lind K, Edman A, Karlsson I, Sjogren M, Wallin A. Relationship between depressive symptomatology and the subcortical brain syndrome in dementia. Int. J. Geriatr. Psychiatry 17(8), 774-778 (2002).
24. Reifler BV, Larson E, Teri L, Poulsen M. Dementia of the Alzheimer's type and depression. J. Am. Geriatz. Soc. 34(12), 855-859 (1986).
25. Raskind MA. The clinical interface of depression and dementia. J. Clin. Psychiatry 59(Suppl. 10), 9-12 (1998).
26. Sultzer DL, Gray KF, Gunay I, Wheatley MV, Mahler ME. Does behavioral improvement with haloperidol or trazdone treatment depend on psychosis or mood symptoms in patients with dementia? J. Am. Geriatr. Soc. 49(10), 1294-1300 (2001).
27. Alexopoulos GS. The assessment and treatment of depressed-demented patients. In: Geriatric Psychopharmacology. Nelson JC (Ed.). Marcel Decker, Inc., NY, USA and Basel, Switzerland (1998).
28. Rummans TA, Lauterbach EC, Coffey CE et al. Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. J. Neuropsyhiatry Clin. Neurosci. 11(2), 176-189 (1999).
29. Naranjo CA, Herrmann N, Mittmann N, Bremner KE. Recent advances in geriatric psychopharmacology. Drugs Aging 7(3), 184-202 (1995).
30. Reifler BV, Teri L, Raskind M et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am. J. Psychiatry 146, 45-49 (1989).
31. Tariot PN, Cohen RM, Sunderland T et al. L-Deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch. Gen. Psychiatry 44, 427-433 (1987).
32. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicenter study. Br. J. Psychiatry 157, 894-901 (1990).
33. Eriksson S, Sylversen S. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with our without concomitant dementia. Acta. Psychiatr. Scand. 86, 138-145 (1992).
34. Katz IR, Simpson GM, Curlik SM et al. Pharmacologic treatment of major depression for elderly patients in residential care settings. J. Clin. Psychol. 519(Suppl. 1), 41-47 (1990).
35. Raji MA, Brady SR. Mirtazapine for treatment of depression and comorbidities in Alzheimer's disease. Ann. Pharmacother. 35(9), 1024-1027 (2001).
36. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr. Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am. J. Geriatr. Psychiatry 10(5), 541-550 (2002).
37. Fuchs A, Hehnke U, Erhart CH et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry 25, 37-41 (1993).
38. Teri L, Reifler BV, Veith RC et al. Imipramine in treatment of depressed Alzheimer's patients: impact on cognition. J. Gerontol. B. Psychol. Sci. Soc. Sci. 6, 372-377 (1991).
39. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int. J. Geriatr. Psychiatry 13(2), 100-108 (1998).
40. Taragano FE, Lyketsos CG, Mangone CA et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38, 246-252 (1997).
41. Borson S, Scanlan JM, Doane K, Gray S. Antidepressant prescribing in nursing home: is there a place for tricyclics? Int. J. Geriatr. Psychiatry 17(12), 1140-1145 (2002).
42. Burt T. Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents. Curr. Psychiatry Rep. 2(6), 473-478 (2000).
43. Robert P. Understanding and managing behavioral symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr. Med. Res. Opin. 18(3), 156-171 (2002).
44. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 47(4), 876-883 (1996).
45. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int. J. Clin. Pract. Suppl. 127, 20-36 (2002).
46. Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J. Clin. Psychiatry 61(7), 487-492 (2000).
47. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer's disease. Arch. Neurol. 56(11), 1388-1393 (1999).
48. Trinh N-H, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease. JAMA 289 (2), 210-216 (2003).
49. Alexopoulos GS. New concepts for prevention and treatment of late-life depression. Am. J. Psychiatry 158, 835-858 (2001).
50. Narang PK, Cutler NR. Pharmacotherapy in Alzheimer's disease: basis and rationale. Prog. Neuropsychopharmacol. Biol. Psychiatry 10(3-5), 519-531 (1986).
51. Roccaforte WH, Burke WJ. Use of psychostimulants for the elderly. Hosp. Community Psychiatry 41(12), 1330-1333 (1990).
52. Kaplitz SE. Withdrawn, apathetic geriatric patients responsive to methylphenidate. J. Am. Geriatr. Soc. 23, 271-276 (1975).
53. Galynker I, Ieronimo C, Miner C, Rosenblum J, Vilkas N, Rosenthal R. Methylphenidate treatment of negative symptoms in patients with dementia. J. Neuropsychiatry Clin. Neurosci. 9(2), 231-239 (1997).
54. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr. Clin. North Am. 19(3), 515-545 (1996).
55. Burn DJ. Depression in Parkinson's disease. Eur. J. Neurol. 9(Suppl. 3), 44-45 (2002).
56. Valldeoriola F, Nobbe FA, Tolosa E. Treatment of behavioural disturbances in Parkinson's disease. J. Neural Transm. Suppl. 51, 175-204 (1997).
57. Cummings JL. The dementias of Parkinson's disease: prevalence, characteristics, neurobiology and comparison with dementia of the Alzheimer type. Eur. Neurol. 28(Suppl. 1), 15-23 (1988).
58. Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson's disease. J. Neurol. 248(Suppl. 3), 12-21 (2001).
59. Kaufer DI. Pharmacological therapy of dementia with Lewy bodies. J. Geriatr. Psychiatry Neurol. 15(4), 224-232 (2002).
60. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361(9360), 799-808 (2003).
61. Weintraub D, Lippmann SB. ECT for major depression and mania with advanced dementia. J. ECT 17(1), 65-67 (2001).
62. Rao V, Lyketsos CG. The benefits and risks of ECT for patients with primary dementia who also suffer from depression. Int. J. Geriatr. Psychiatry 15(8), 729-735 (2000).
63. Andrade C, Kurinji S. Continuation and maintenance ECT: a review of recent research. J. ECT 18(3), 149-158 (2002).
64. George MS. New methods of minimally invasive brain modulation as therapies in psychiatry: TMS, MST, VNS and DBS. Zhonghua Yi Xue Za Zhi (Taipei) 65(8), 349-360 (2002).
65. Sackeim HA, Keilp JG, Rush AJ et al. The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression. Neuropsychiatry Neuropsychol. Behav. Neurol. 14(1), 53-62 (2001).
66. Dodrill CB, Morris GL. Effects of vagal nerve stimulation on cognition and quality of life in epilepsy. Epilepsy Behav. 2(1), 46-53 (2001).
67. Sjogren MJ, Hellstrom PT, Jonsson MA, Runnerstam M, Silander HC, Ben-Menachem E. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. J. Clin. Psychiatry 63(11), 972-980 (2002).
68. Teri L, Gallagher-Thompson D. Cognitive-behavioral interventions for treatment of depression in Alzheimer's patients. Gerontologist 31(3), 413-413 (1991).
69. Teri L, Logsdon RG, Uomoto J et al. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J. Gerontol. B. Psychol. Sci. Soc. Sci. 4, 159-166 (1997).
70. Clare L, Wilson BA, Carter G, Breen K, Berrios GE, Hodges JR. Depression and anxiety in memory clinic attenders and their carers: implications for evaluating the effectiveness of cognitive rehabilitation interventions. Int. J. Geriatr. Psychiatry 17(10), 962-967 (2002).
71. Fugh-Berman A, Cott JM. Dietary supplements and natural products as psychotherapeutic agents. Psychosom. Med. 61(5), 712-728 (1999).
72. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 287(14), 1807-1814 (2002).
73. Tesch BJ. Herbs commonly used by women: an evidence-based review. Dis. Mon. 48(10), 671-696 (2002).
74. Ernst E. Herbal medications for common ailments in the elderly. Drugs. Aging 15(6), 423-428 (1999).
75. Hammerness P, Basch E, Ulbricht C et al. Natural Standard Research Collaboration. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 44(4), 271-282 (2003).
76. Sandyk R. L-tryptophan in neuropsychiatric disorders: a review. Int. J. Neurosci. 67(1-4), 127-144 (1992).
77. Freeman MP. Omega-3 fatty acids in psychiatry: a review. Ann. Clin. Psychiatry 12(3), 159-165 (2000).
78. Alessi CA, Schnelle JE Approach to sleep disorders in the nursing home setting. Sleep Med. Rev. 4(1), 45-56 (2000).
79. Montgomery P, Dennis J. Physical exercise for sleep problems in adults aged 60+. Cochrane Database Syst. Rev. 4, CD003404 (2002).
80. Schindler SD, Graf A, Fischer P, Tolk A, Kasper S. Paranoid delusions and hallucinations and bright light therapy in Alzheimer's disease. Int. J. Geriatr. Psychiatry 17(11), 1071-1072 (2002).
81. Lyketsos CG, Lindell Veiel L, Baker A, Steele C. A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. Int. J. Geriatr Psychiatry 14(7), 520-525 (1999).
82. Katz IR. Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias. J. Clin. Psychiatry 59(Suppl. 9), 38-44 (1998).